Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alpine Immune Sciences, Inc.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Adult 18 to 75 years old at screening
2. Pathologically-confirmed, locally advanced or metastatic unresectable solid tumor of an acceptable histology
Part A (Dose Escalation)
1. that is refractory or resistant to standard therapy, including checkpoint inhibitor(s) if approved
2. or for which standard or curative therapy is not available
Part B (Dose Expansion)
1. metastatic cutaneous melanoma
2. PD-L1-positive cancers (other than cutaneous melanoma or renal cell carcinoma)
3. metastatic renal cell carcinoma
3. Protocol-defined measurable disease
4. Available tumor biopsy representative of current disease
5. ECOG performance status grade 0-2
6. Life expectancy of ≥ 3 months
7. Recovery to ≤ Grade 1 for any non-laboratory toxicity resulting from previous anticancer therapy prior to first dose of ALPN-202 (except alopecia, hearing loss, ≤ Grade 2 neuropathy or endocrinopathy managed with replacement therapy)
8. Adequate baseline hematologic, renal, and hepatic function
You may not be if
1. History of ≥ Grade 3 immune-related adverse event leading to treatment discontinuation
2. Active or prior pneumonitis or interstitial lung disease
3. Presence of any active central nervous system metastases
4. Prior organ allograft or allogeneic hematopoietic stem cell transplantation
5. Any serious or uncontrolled health condition, which, in the opinion of the Investigator, would place the subject at undue risk from the study, impair the ability of the subject to receive protocol specified therapy, or interfere with the interpretation of study results.
6. Receipt of any protocol-restricted therapy within the timeframes indicated:
